10.00SEK-4.31%Mkt Cap: 206.05M SEKP/E: —Last update: 2026-06-01
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap206.05M SEK
Enterprise Value205.46M SEK
Revenue (TTM)76.45M SEK
Gross Profit89.55M SEK
Net Income (TTM)127.24M SEK
Revenue/Share3.710 SEK
Last Price10.00 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees28
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0007789409
Valuation
P/E (Trailing)—
P/E (Forward)522.50
PEG—
EV/EBITDA-3.50
EV/Revenue2.69
P/S2.82
P/B0.38
EPS (TTM)-4.68
EPS (Forward)0.02
52W Range
5.42114% of range38.10
52W High38.10 SEK
52W Low5.421 SEK
Profitability
Gross Margin58.76%
Oper. Margin-52.10%
EBITDA Margin-76.84%
Profit Margin83.49%
ROE22.70%
ROA18.95%
Growth
Revenue Growth-81.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-250.69M SEK
CapEx (TTM)139.64M SEK
FCF Margin-321.78%
FCF Yield-119.39%
Net Debt-9.87M SEK
Net Debt/EBITDA0.17
Balance Sheet
Debt/Equity0.10
Current Ratio3.03
Quick Ratio0.79
Book Value/Sh27.21 SEK
Cash/Share3.239 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:125
Split DateOct 17, 2025
Analyst Consensus
Rating—
Target (Mean)15.00 SEK
Target Range15.00 SEK – 15.00 SEK
# Analysts1
Ownership
Shares Out.20.61M
Float15.03M
Insiders41.04%
Institutions6.26%
Technical
SMA 509.035 (+10.7%)
SMA 20014.39 (-30.5%)
Beta0.89
S&P 52W Chg27.70%
Avg Vol (30d)72.56K
Avg Vol (10d)37.21K
Technical Indicators
RSI (14)51.5
MACD0.5379
MACD Signal0.6454
MACD Hist.-0.1075
BB Upper12.06 SEK
BB Middle10.60 SEK
BB Lower9.137 SEK
BB Width27.58%
ATR (14)0.9283 SEK
Vol Ratio (20d)1.43x